Powder X-ray diffraction method for the quantification of cocrystals in the crystallization mixture
暂无分享,去创建一个
Luis Padrela | S. Velaga | L. Padrela | Sitaram P Velaga | Edmundo Gomes de Azevedo | E. G. de Azevedo
[1] Katsuhiko Yamamoto,et al. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. , 2010, International journal of pharmaceutics.
[2] T. Fukami,et al. Characterization of multicomponent crystal formed between indomethacin and lidocaine , 2009, Drug development and industrial pharmacy.
[3] Amjad Alhalaweh,et al. Bioavailability of indomethacin‐saccharin cocrystals , 2010, The Journal of pharmacy and pharmacology.
[4] D. Bugay,et al. Quantitation of cefepime.2HCl dihydrate in cefepime.2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques. , 1996, Journal of pharmaceutical and biomedical analysis.
[5] S. Velaga,et al. Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization , 2008, Pharmaceutical Research.
[6] William Jones,et al. Improving Mechanical Properties of Crystalline Solids by Cocrystal Formation: New Compressible Forms of Paracetamol , 2009 .
[7] J. Tantry,et al. Processing-induced phase transitions of theophylline--implications on the dissolution of theophylline tablets. , 2007, Journal of pharmaceutical sciences.
[8] Rumi Faizer,et al. Quantification of crystallinity in blends of lyophilized and crystalline MK-0591 using x-ray powder diffraction , 1995 .
[9] S. Velaga,et al. Hansen solubility parameter as a tool to predict cocrystal formation. , 2011, International journal of pharmaceutics.
[10] Thomas Rades,et al. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[11] W Press,et al. Crystalline solids. , 1980, Science.
[12] N. Rodríguez-Hornedo,et al. Transformation pathways of cocrystal hydrates when coformer modulates water activity. , 2010, Journal of pharmaceutical sciences.
[13] A. Shete,et al. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride , 2010, Drug development and industrial pharmacy.
[14] Lynne S. Taylor,et al. Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.
[15] K R Morris,et al. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. , 2001, Advanced drug delivery reviews.
[16] Kwok Chow,et al. Engineering of pharmaceutical materials: an industrial perspective. , 2008, Journal of pharmaceutical sciences.
[17] Luis Padrela,et al. Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[18] P. York. Solid-state properties of powders in the formulation and processing of solid dosage forms , 1983 .
[19] S. Childs,et al. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome , 2009 .
[20] R. Suryanarayanan,et al. Quantitation of crystallinity in substantially amorphous pharmaceuticals and study of crystallization kinetics by X-ray powder diffractometry , 2000, Powder Diffraction.
[21] Orn Almarsson,et al. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2003, Chemical communications.
[22] Aeri Park,et al. Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.
[23] C. Strachan,et al. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[24] Adrian C. Williams,et al. Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry--exploring preferred orientation effects. , 2002, Journal of Pharmaceutical and Biomedical Analysis.
[25] Thomas Rades,et al. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. , 2009, Journal of pharmaceutical and biomedical analysis.
[26] P York,et al. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.
[27] A. Bansal,et al. Quantification of olanzapine polymorphs using powder X-ray diffraction technique. , 2007, Journal of pharmaceutical and biomedical analysis.
[28] Sarsvatkumar Patel,et al. Effect of sample preparation method on quantification of polymorphs using PXRD , 2010, Pharmaceutical development and technology.
[29] Ning Shan,et al. The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.
[30] T. Rades,et al. Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. , 1999, International journal of pharmaceutics.
[31] P. Schroeder,et al. Accurate quantification of quartz and other phases by powder X-ray diffractometry , 1997 .
[32] R. Banerjee,et al. Variable-temperature powder X-ray diffraction of aromatic carboxylic acid and carboxamide cocrystals. , 2007, Chemistry, an Asian journal.
[33] K. Steffens,et al. Quantifying Low Amorphous or Crystalline Amounts of Alpha‐Lactose‐Monohydrate Using X‐Ray Powder Diffraction, Near‐Infrared Spectroscopy, and Differential Scanning Calorimetry , 2004, Drug development and industrial pharmacy.
[34] Naír Rodríguez-Hornedo,et al. Solubility Advantage of Pharmaceutical Cocrystals , 2009 .